Scholarlink

Background <p><i>KRAS</i><sup>G12C</sup> alterations are present in ~13% of lung adenocarcinomas. AZD4625 is a covalent small molecule inhibitor that selectively binds and inhibits GDP-KRAS<sup>G12C</sup>, leading to reduced cell viability and protein signaling responsible for tumor survival in models with this gain-of-function alteration.</p> Methods <p>We studied short-term changes in signaling and mechanisms of primary resistance to AZD4625 in twelve <i>KRAS</i><sup>G12C</sup> lung adenocarcinoma patient-derived xenografts (PDX) and six organoids derived from these twelve models.</p> Results <p>Sustained tumor regression in four (33%) PDXs was observed while the remaining eight models were intrinsically resistant to AZD4625. Organoid responses to AZD4625 were concordant with their derived PDXs. Acute AZD4625 exposure significantly decreased gene expression of the ERK1/2 negative regulator, <i>DUSP6</i>, in all models while protein MAPK and AKT/mTOR signals were downregulated more frequently in the AZD4625-sensitive than AZD4625-resistant cohorts. Analyzing PDX transcriptomes and proteomes identified mTOR signaling as a putative mechanism of primary resistance to AZD4625.</p> Conclusions <p>Our findings confirm AZD4625 as a highly active KRAS<sup>G12C</sup> inhibitor. This data also supports the use of PDX models in understanding resistance mechanisms that may be leveraged to develop more active combination therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月11日

查看全文
  • Joshua C. Rosen,
  • Pinjiang Cao,
  • Nhu-An Pham,
  • Matthew Waas,
  • Quan Li,
  • Katrina Hueniken,
  • Mutian Wang,
  • Roya Navab,
  • Leanne Wybenga-Groot,
  • Nikolina Radulovich,
  • Michael Niedbala,
  • Alex Koers,
  • Sarah Ross,
  • Michael F. Moran,
  • Adrian Sacher,
  • Ming-Sound Tsao

摘要

Background

KRASG12C alterations are present in ~13% of lung adenocarcinomas. AZD4625 is a covalent small molecule inhibitor that selectively binds and inhibits GDP-KRASG12C, leading to reduced cell viability and protein signaling responsible for tumor survival in models with this gain-of-function alteration.

Methods

We studied short-term changes in signaling and mechanisms of primary resistance to AZD4625 in twelve KRASG12C lung adenocarcinoma patient-derived xenografts (PDX) and six organoids derived from these twelve models.

Results

Sustained tumor regression in four (33%) PDXs was observed while the remaining eight models were intrinsically resistant to AZD4625. Organoid responses to AZD4625 were concordant with their derived PDXs. Acute AZD4625 exposure significantly decreased gene expression of the ERK1/2 negative regulator, DUSP6, in all models while protein MAPK and AKT/mTOR signals were downregulated more frequently in the AZD4625-sensitive than AZD4625-resistant cohorts. Analyzing PDX transcriptomes and proteomes identified mTOR signaling as a putative mechanism of primary resistance to AZD4625.

Conclusions

Our findings confirm AZD4625 as a highly active KRASG12C inhibitor. This data also supports the use of PDX models in understanding resistance mechanisms that may be leveraged to develop more active combination therapies.